Dr. Reddy's Laboratories Limited (RDY)
NYSE: RDY · Real-Time Price · USD
14.03
+0.06 (0.43%)
At close: Apr 28, 2026, 4:00 PM EDT
14.26
+0.23 (1.64%)
After-hours: Apr 28, 2026, 7:53 PM EDT
Dr. Reddy's Laboratories Revenue
Dr. Reddy's Laboratories had revenue of 87.27B INR in the quarter ending December 31, 2025, with 4.41% growth. This brings the company's revenue in the last twelve months to 345.83B, up 11.09% year-over-year. In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B with 16.61% growth.
Revenue (ttm)
345.83B INR
Revenue Growth
+11.09%
P/S Ratio
3.10
Revenue / Employee
12,435,044 INR
Employees
27,811
Market Cap
11.92B USD
Revenue Chart
* This company reports financials in INR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
| Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
| Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
| Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
| Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Teva Pharmaceutical Industries | 17.26B |
| Viatris | 14.30B |
| Elanco Animal Health | 4.72B |
| United Therapeutics | 3.18B |
| Amneal Pharmaceuticals | 3.02B |
| Neurocrine Biosciences | 2.86B |
| Hims & Hers Health | 2.35B |
| Lantheus Holdings | 1.54B |
RDY News
- 4 days ago - Dr. Reddy's to announce Q4 and FY26 results on May 12, 2026 - Business Upturn
- 5 days ago - Why are Dr Reddy’s shares falling nearly 2% today? Explained - Business Upturn
- 5 days ago - Broker Calls Today: Infosys Gets Mixed Bag, Dr Reddy's Downgraded, Cipla Bullish on Ventolin Approval — Full Analyst Roundup - Business Upturn
- 5 days ago - A Look at Dr Reddy's Laboratories Ltd (RDY) After 5.8% Gain -- GF Value $15.06 vs Price $13.58 - GuruFocus
- 5 days ago - Dr. Reddy's (RDY) Stock Downgraded by Goldman Sachs - GuruFocus
- 5 days ago - Dr. Reddy's (RDY) Shares Surge on Generic Drug News - GuruFocus
- 5 days ago - Nifty 50 top gainers today, April 23: Dr. Reddy's Laboratories, Cipla, Jio Financial Services, Adani Enterprises and more - Business Upturn
- 6 days ago - Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77% - Business Upturn